Texas § 1369.654 PROHIBITION ON MULTIPLE PRIOR AUTHORIZATIONS.

Texas Statutes

§ 1369.654 — PROHIBITION ON MULTIPLE PRIOR AUTHORIZATIONS.

Texas § 1369.654

Code INInsurance Code

This text of Texas § 1369.654 (PROHIBITION ON MULTIPLE PRIOR AUTHORIZATIONS.) is published on Counsel Stack Legal Research, covering Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Tex. Insurance Code Code Ann. § 1369.654 (2026).

Text

Sec. 1369.654. PROHIBITION ON MULTIPLE PRIOR AUTHORIZATIONS.

(a)A health benefit plan issuer that provides prescription drug benefits may not require an enrollee to receive more than one prior authorization annually of the prescription drug benefit for a prescription drug prescribed to treat an autoimmune disease, hemophilia, or Von Willebrand disease.

(b)This section does not apply to:

(1)opioids, benzodiazepines, barbiturates, or carisoprodol;

(2)prescription drugs that have a typical treatment period of less than 12 months;

(3)drugs that:

(A)have a boxed warning assigned by the United States Food and Drug Administration for use; and

(B)must have specific provider assessment; or

(4)the use of a drug approved for use by the United States Food and Drug Administration in a manner ot

Free access — add to your briefcase to read the full text and ask questions with AI

Sec. 1369.654. PROHIBITION ON MULTIPLE PRIOR AUTHORIZATIONS. (a) A health benefit plan issuer that provides prescription drug benefits may not require an enrollee to receive more than one prior authorization annually of the prescription drug benefit for a prescription drug prescribed to treat an autoimmune disease, hemophilia, or Von Willebrand disease.
(b) This section does not apply to:
(1) opioids, benzodiazepines, barbiturates, or carisoprodol;
(2) prescription drugs that have a typical treatment period of less than 12 months;
(3) drugs that:
(A) have a boxed warning assigned by the United States Food and Drug Administration for use; and
(B) must have specific provider assessment; or
(4) the use of a drug approved for use by the United States Food and Drug Administration in a manner other than the approved use.
SUBCHAPTER Q. CLINICIAN-ADMINISTERED DRUGS